Dillard's vs Kohls
DDS and KSS side by side, both in general merchandise stores. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How DDS and KSS compare
Dillard's is the larger company, worth 3.7 times as much as Kohls ($10.3B against $2.8B).
Dillard's grew revenue faster over the last twelve months (0.21% versus −2.9% for Kohls).
Dillard's keeps more of each dollar of sales as profit, with a net margin of 10.3% compared with 1.7% at Kohls.
Both pay dividends: Dillard's yields 0.18% and Kohls 2.1%.
Kohls scores higher on the StockData Score (14 against 11 for Dillard's), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | DDS | KSS |
|---|---|---|
| Size and price | ||
| Market cap | $10.3B | $2.8B |
| Share price | $660.84 | $24.31 |
| Change, 1 year | 8.6% | 52.6% |
| Change, 5 years | 118% | −58.2% |
| Beta (5Y) | 1.30 | 1.64 |
| Employees | 29K | 138K |
| StockData Score | ||
| Total score | 11 | 14 (better) |
| Valuation score | 1 | 5 (better) |
| Growth score | 1 | 2 (better) |
| Performance score | 3 (better) | 0 |
| Health score | 2 | 4 (better) |
| Dividend score | 4 (better) | 3 |
| Valuation | ||
| P/E | – | 10.5× |
| P/S | 1.6× | 0.2× (better) |
| P/B | 4.9× | 0.7× (better) |
| EV/EBITDA | 9.0× | 2.5× (better) |
| P/FCF | 16.3× | 2.7× (better) |
| FCF yield | 6.2% | 37.5% (better) |
| Fair value | $724.85 | $57.32 |
| Margin of safety | 8.8% | 57.6% (better) |
| Growth | ||
| Revenue growth (TTM) | 0.21% (better) | −2.9% |
| Revenue growth, 5Y average | 8.2% (better) | −0.54% |
| Net income growth (TTM) | 18.4% | 29.8% (better) |
| EPS growth (TTM) | – | 25.4% |
| Profitability | ||
| Gross margin | 39.8% | 41.2% (better) |
| Operating margin | – | 3.8% |
| Net margin | 10.3% (better) | 1.7% |
| FCF margin | 9.6% (better) | 6.7% |
| Return on equity | 33.8% (better) | 6.7% |
| Return on invested capital | – | 9.7% |
| Financial health | ||
| Debt / equity | – | 0.32 |
| Net debt / EBITDA | – | 0.39 |
| Current ratio | 3.03 (better) | 1.49 |
| Altman Z-score | 8.62 (better) | 1.73 |
| Piotroski F-score | 6 | 6 |
| Dividends and buybacks | ||
| Dividend yield | 0.18% | 2.1% (better) |
| Payout ratio | 71.3% | 20.7% |
| Years of dividend growth | 12 (better) | 0 |
| Dividend growth, 5Y average | 120% (better) | −6.6% |
| Shareholder yield | 0.18% | 2.1% (better) |
| Ownership | ||
| Held by institutions | 53.6% | 106% |
| Held by insiders | 48.6% | 4.5% |
| Insider net buying, 12 months | −$244K (better) | −$1.6M |
| Short interest, % of float | – | 28.7% |
Go deeper
- DDS stock overview
- DDS income statement
- DDS valuation and score
- KSS stock overview
- KSS income statement
- KSS valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.